Clomiphene citrate is a fertility medication that tricks your brain into producing more of the hormones needed for ovulation. It works by blocking estrogen receptors in the hypothalamus, which causes your body to ramp up its own reproductive hormone production. It’s one of the most commonly prescribed first-line treatments for women who aren’t ovulating regularly, and it’s also used off-label in men with low testosterone.
How Clomiphene Works in the Body
Your brain constantly monitors estrogen levels to decide how much reproductive hormone to produce. When estrogen is high, the hypothalamus dials back production of gonadotropin-releasing hormone (GnRH), which in turn reduces the pituitary gland’s output of FSH (follicle-stimulating hormone) and LH (luteinizing hormone). This is the normal feedback loop that keeps your cycle in balance.
Clomiphene is a selective estrogen receptor modulator. It competes with estrogen for binding sites in the hypothalamus, essentially blocking the brain from “seeing” how much estrogen is actually circulating. Your hypothalamus interprets this as low estrogen and responds by increasing GnRH output. That triggers the pituitary to release more FSH and LH. The surge in FSH stimulates the ovaries to develop follicles, and the rise in LH triggers ovulation. The medication doesn’t add hormones from outside your body. It manipulates your existing hormone signaling to produce a stronger natural response.
Primary Use: Inducing Ovulation
Clomiphene is most often prescribed for women with anovulation, meaning their ovaries don’t release an egg regularly or at all. This includes many women with polycystic ovary syndrome (PCOS), one of the most common causes of irregular ovulation. The standard protocol is 50 mg taken by mouth daily for five consecutive days, usually starting on the fifth day of your menstrual period. If you don’t have regular cycles, treatment can begin at any time.
The ovulation success rate is high. About 80% of anovulatory women will ovulate on clomiphene, though the pregnancy rate is lower, around 40% overall. The gap between ovulation and pregnancy exists because conception depends on many other factors: sperm quality, tubal health, uterine lining thickness, and timing. Per-cycle pregnancy rates typically fall between 10% and 20%, but cumulative rates climb with repeated cycles. After six cycles, pregnancy rates can reach around 60%.
If you don’t ovulate at the starting dose, your provider may increase it in subsequent cycles. Treatment is generally limited to about six ovulatory cycles. If you ovulate but don’t conceive within that window, clomiphene is typically considered a treatment failure, and your provider will discuss alternatives.
Clomiphene vs. Letrozole for PCOS
For women with PCOS specifically, letrozole (an aromatase inhibitor) has become a strong competitor. In a head-to-head comparison of 220 women with PCOS, letrozole produced a live birth rate of 25.4% compared to 10.9% for clomiphene. Pregnancy rates were also significantly higher with letrozole (29% vs. 15.4%). Letrozole was also more likely to produce a single mature follicle (77.2% vs. 52.7%), which reduces the risk of twins or triplets.
Despite these results, clomiphene remains widely used because it’s inexpensive, well-studied over decades, and effective for many causes of anovulation beyond PCOS. Your provider’s recommendation will depend on your specific diagnosis and medical history.
Off-Label Use in Men
Clomiphene works through the same basic mechanism in men. By blocking estrogen receptors in the hypothalamus and pituitary, it increases LH and FSH production. In men, LH stimulates the testes to produce more testosterone, while FSH supports sperm production. This makes clomiphene an appealing alternative to testosterone replacement therapy (TRT) for men with low testosterone who want to preserve their fertility.
The key advantage over TRT is that testosterone injections or gels actually suppress the body’s own hormone production, which can drastically reduce sperm count. Clomiphene does the opposite: it maintains high FSH and LH levels along with testosterone levels inside the testes, improving both testosterone and sperm parameters simultaneously. Studies show clomiphene raises testosterone to around 500-570 ng/dL in men with hypogonadism. That’s comparable to testosterone gels (around 412 ng/dL) though lower than what injections achieve (around 1,014 ng/dL).
A meta-analysis found that men on clomiphene saw sperm concentration increase by an average of 8.38 million per milliliter and sperm motility improve by about 8%. Sperm shape (morphology) showed slight improvement that wasn’t statistically significant. For men dealing with both low testosterone symptoms and fertility concerns, clomiphene offers a way to address both problems at once.
Risk of Multiple Pregnancies
Because clomiphene stimulates follicle development, it can cause more than one egg to mature and release in a single cycle. A large nationwide cohort study found that the multiple pregnancy rate with clomiphene was 5.2%, compared to 1.4% in women who conceived without the drug. That’s roughly a fourfold increase in risk. The vast majority of these are twins (5.1%), while triplets or higher-order multiples are rare at 0.13%.
Multiple pregnancies carry higher risks of preterm birth, low birth weight, and complications for both mother and babies. The same study found increased rates of perinatal complications even in singleton pregnancies conceived with clomiphene. This is one reason ultrasound monitoring during treatment is recommended, particularly in the first cycle, to check how many follicles are developing and adjust the dose if needed.
Monitoring During Treatment
Most providers will monitor your cycle with blood tests and transvaginal ultrasound. A common schedule involves baseline checks around cycle day 3 (to rule out ovarian cysts and confirm hormone levels are appropriate to start), followed by monitoring around cycle day 12 and possibly days 14-16 to track follicle growth and time ovulation. Blood work typically includes estrogen, FSH, LH, and progesterone levels. Progesterone measured after expected ovulation confirms whether an egg was actually released.
If a cyst is found on the baseline ultrasound, that cycle is usually canceled. Stimulating ovaries that already have an enlarged cyst can lead to complications.
Side Effects
Most women tolerate clomiphene well, but side effects are common enough that you should know what to expect. Hot flashes are the most frequently reported, caused by the same estrogen-blocking mechanism that makes the drug work. Mood changes, bloating, breast tenderness, and headaches also occur. Some women experience visual disturbances like blurring, spots, or flashes of light. These visual symptoms are generally reversible but should be reported to your provider promptly, as they may warrant stopping the medication.
Ovarian hyperstimulation syndrome (OHSS), where the ovaries swell and fluid leaks into the abdomen, is a more serious but rare complication with clomiphene alone. One study of 830 clomiphene-only cycles found clinically significant OHSS in just 3 cases, a rate of 0.36%. OHSS is far more common with injectable fertility drugs, so clomiphene’s low risk profile is one of its advantages as a first-line treatment.
Who Should Not Take Clomiphene
The FDA lists several contraindications. You should not take clomiphene if you have liver disease or a history of liver dysfunction, ovarian cysts not caused by PCOS, unexplained abnormal uterine bleeding, uncontrolled thyroid or adrenal disorders, or a pituitary tumor. It is also contraindicated during pregnancy, as it offers no benefit and poses potential risks. Before starting treatment, your provider will typically evaluate these factors to confirm clomiphene is appropriate for your situation.